Clinical Trial Update: RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery [Phase 1]

View source ↗

Summary

A phase 1 trial of RO4929097 and vismodegib for metastatic or unresectable breast cancer was terminated; no results are reported in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Erivedge (vismodegib)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Status: TERMINATED